Literature DB >> 2280355

Pharmacokinetics of atenolol enantiomers in humans and rats.

R Mehvar1, M E Gross, R N Kreamer.   

Abstract

Single dose pharmacokinetics of atenolol (AT) enantiomers was studied in human volunteers and in rats. After oral administration of 50 mg of racemic AT to humans, the areas under the plasma concentration-time curves (AUCs; mean +/- SD) were 1640 +/- 602 and 1860 +/- 652 (ng/mL)h for the S(-)- and R(+)-enantiomers, respectively (p less than 0.05). The small difference in the AUC was a reflection of a slight, but statistically significant (p less than 0.05) difference in the renal clearance (CLr, mL/min) of the enantiomers [129 +/- 32, S(-)-AT; 120 +/- 29, R(+)-AT]. However, the two enantiomers were not different from each other (p greater than 0.05) with respect to the volume of distribution (V lambda, L/kg) [0.879 +/- 0.342, S(-)-AT; 0.790 +/- 0.255, R(+)-AT] or the terminal elimination rate constant (lambda z, h-1) [0.113 +/- 0.038, S(-)-AT; 0.114 +/- 0.036, R(+)-AT]. After iv administration of 10 mg/kg of the racemic AT to rats, the R(+)-enantiomer achieved higher AUC values [(ng/mL)h] compared with its antipode (p less than 0.05) [3630 +/- 1040, S(-)-AT; 4020 +/- 1080, R(+)-AT]. Similar to the human results, this difference was due to a stereoselective renal clearance (mL/min/kg) in favor of S(-)-AT [14.9 +/- 5.78, S(-)-AT; 13.0 +/- 4.88, R(+)-AT; p less than 0.05].(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2280355     DOI: 10.1002/jps.2600791007

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

1.  A cell-based molecular transport simulator for pharmacokinetic prediction and cheminformatic exploration.

Authors:  Xinyuan Zhang; Kerby Shedden; Gus R Rosania
Journal:  Mol Pharm       Date:  2006 Nov-Dec       Impact factor: 4.939

Review 2.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

Review 3.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 4.  Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods.

Authors:  R Mehvar; F Jamali
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

5.  Relationship among physicochemical properties, skin permeability, and topical activity of the racemic compound and pure enantiomers of a new antifungal.

Authors:  L Wearley; B Antonacci; A Cacciapuoti; S Assenza; I Chaudry; C Eckhart; N Levine; D Loebenberg; C Norris; R Parmegiani
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

6.  Toxicity of beta-blockers in a rat whole embryo culture: concentration-response relationships and tissue concentrations.

Authors:  S Klug; R Thiel; R Schwabe; H J Merker; D Neubert
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

7.  Atenolol Renal Secretion Is Mediated by Human Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Proteins.

Authors:  Jia Yin; Haichuan Duan; Yoshiyuki Shirasaka; Bhagwat Prasad; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2015-09-15       Impact factor: 3.922

8.  Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction.

Authors:  Laura Letendre; Mark Scott; Glenn Dobson; Ismael Hidalgo; Bruce Aungst
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

9.  Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint.

Authors:  T J van Steeg; J Freijer; M Danhof; E C M de Lange
Journal:  Br J Pharmacol       Date:  2007-04-10       Impact factor: 8.739

10.  Design, Development and Optimization of S (-) Atenolol Floating Sustained Release Matrix Tablets Using Surface Response Methodology.

Authors:  P T Gunjal; M B Shinde; V S Gharge; S V Pimple; M K Gurjar; M N Shah
Journal:  Indian J Pharm Sci       Date:  2015 Sep-Oct       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.